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Welcome to the ﬁ   rst issue of the international open 
access journal Stem Cell Research & Th  erapy, edited by 
Professor Rocky Tuan, of the University of Pittsburgh, 
and Professor Timothy O’Brien, of the National Univer-
sity of Ireland, Galway.
Stem Cell Research & Th  erapy aims to be the major 
forum for translational research into stem cell therapies. 
Th   e journal has a special emphasis on basic, translational, 
and clinical research into stem cell therapeutics, 
including animal models, and clinical trials.
Stem cell research for therapeutic purposes has largely 
used adult stem cell sources. Embryonic stem cell 
research has enormous potential and also has major 
hurdles to overcome, not the least of which are ethical in 
nature. Funding for research into embryonic stem cells 
has also been in a state of transition. Th   e change in US 
policy and subsequent National Institutes of Health 
guidelines allowing funding for human embryonic 
research has moved the use of stem cells of embryonic 
origin back into the spotlight [1]. Although legislation 
throughout the world varies, the international research 
community is striving to disseminate critical knowledge 
and useful ideas to aid the progress of our expertise in 
this area, and our open access policy will promote this.
Why is stem cell research important?
Stem cell research has great potential in the treatment of 
as-of-yet incurable diseases, including Huntington disease 
and Parkinson disease, Alzheimer disease, and amyo-
trophic lateral sclerosis. Other, more chronic conditions 
such as congestive cardiac failure, diabetes, and osteo-
arthritis may also respond well to stem cell therapy.
With the knowledge that stem cells can be induced to 
diﬀ   erentiate into specialized cells and that they can 
inﬂ  uence the tissues around them, the potential of stem 
cells as a therapeutic option is great. Recent advances 
have demonstrated that adult somatic cells, called 
induced pluripotent stem cells, can be reprogrammed 
into becoming stem-like in their nature and behavior [2].
Research is currently focused on calibration of the 
process of cell reprogramming, ensuring the quality of 
induced pluripotent stem cells, and modiﬁ  cation of the 
stem cell niche. Future research will increasingly consider 
quality control of stem cell manufacture, delivery to the 
target areas, and architectural aids to ensure optimum 
placement and exposure of the stem cells.
Another important aspect of stem cell therapeutics will 
be a focus on the bioengineering of materials necessary 
to deliver and support stem cells on their therapeutic 
journey. Combinations of stem cell therapy with gene 
therapy will also expand the therapeutic repertoire as the 
eﬀ  ectiveness of the stem cell product may be enhanced 
via genetic modiﬁ  cation.  Th  us, combinations of stem 
cells, biomaterials, and gene therapy may augment the 
therapeutic outcome but will result in complex regulatory 
challenges.
Th   e potential paracrine mode of the therapeutic action 
of stem cells is worthy of substantial attention. Under-
standing the mechanism whereby stem cells heal tissue 
by regulating and interacting with host cells may lead to 
the development of novel therapeutic paradigms that 
may not require the stem cell per se as the therapeutic 
agent.
How and what will we publish?
BioMed Central is launching Stem Cell Research & 
Th  erapy to provide a new forum to highlight the growing 
area of stem cell therapeutics. In this open access journal, 
our research content will be made freely available upon 
publication. Th   is means that readers worldwide will have 
immediate and free access to original research, promot-
ing the immediate and wide distribution of the most 
current developments in the ﬁ  eld [3]. Under our open 
access license, authors retain copyright of their article, 
allowing them, and any third party, to re-use their work 
as long as the authors are given correct attribution [4]. To 
cover the costs of open access, authors of original 
research are asked to pay an article-processing charge 
once their article has been accepted for publication. Th  is 
is a ﬂ  at fee that includes the use of color ﬁ  gures, un-
limited pages, and additional data sets. Indeed, authors 
can upload both audio and visual ﬁ  les alongside their 
manuscript at no extra cost. To ensure permanence and 
high visibility, research published in Stem Cell Research &  © 2010 BioMed Central Ltd
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© 2010 BioMed Central LtdTh  erapy will also be deposited in several international 
bibliographic databases [5].
Stem Cell Research & Th  erapy will publish original 
research as well as regular commissioned articles. Our 
reviews will provide a comprehensive overview of speciﬁ  c 
topics, collating and discussing the ever-changing 
advances in the ﬁ  eld. Th   ere will be a speciﬁ  c focus on the 
therapeutic elements of stem cell research. Commentaries 
and viewpoint articles will be speculative and allow 
authors to be more opinionated in their views. Readers 
are ﬁ  rmly encouraged to participate and can do so by 
submitting letters to the editor on articles published in 
Stem Cell Research & Th  erapy and on any issue in a 
related area. Brief comments can also be posted online 
on any article by using the tools displayed on the article’s 
webpage. Th   ese tools will also allow articles to be shared 
via ‘social media’ services such as Facebook and Twitter, 
reﬂ   ecting the commitment of the journal to dissemi-
nating our articles widely via the most popular and 
modern means.
We welcome your contributions
Stem Cell Research & Th  erapy will provide a platform for 
translational research into stem cell therapy. We are 
delighted to introduce this much-needed journal to the 
stem cell research community, and we welcome your 
responses and submissions. Th  e Editors-in-Chief, sup-
ported by a global Editorial Board [6], are committed to 
making this journal a success, and we look forward to 
receiving your contributions.
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